TY - JOUR
T1 - Relation of natriuretic peptide concentrations to central sleep apnea in patients with heart failure
AU - Calvin, Andrew D.
AU - Somers, Virend K.
AU - Van Der Walt, Christelle
AU - Scott, Christopher G.
AU - Olson, Lyle J.
N1 - Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Somers has served as a Consultant for Respironics, ResMed, Cardiac Concepts, GlaxoSmithKline, Sunovion Pharmaceuticals, and Medtronic Corporation and has been a principal investigator or coinvestigator on research grants funded by the Respironics Foundation, the ResMed Foundation, and the Sorin Corporation. Dr Olson has received research grants from the Medtronic Corporation and the Sorin Corporation. Dr Calvin, Ms van der Walt, and Mr Scott have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Funding Information:
Funding/Support: This work was supported by the Mayo Clinic Clinician-Investigator Training Program (A. D. C.); Mayo Foundation; American Heart Association [ Grant 04-50103Z ]; National Heart Lung and Blood Institute [ Grants HL65176, HL70302, and HL73211 ]; and the National Center for Research Resources (NCRR) [ Grant 1ULI RR024150 ], a component of the National Institutes of Health and the National Institutes of Health Roadmap for Medical Research.
PY - 2011/12
Y1 - 2011/12
N2 - Background: Central sleep apnea (CSA) is frequent among patients with heart failure (HF) and associated with increased morbidity and mortality. Elevated cardiac filling pressures promote CSA and atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) secretion. We hypothesized that circulating natriuretic peptide concentrations predict CSA. Methods:Consecutive patients with HF (n = 44) with left ventricular ejection fraction (LVEF) ≤35% underwent polysomnography for detection of CSA. CSA was defined as an apnea-hypo pnea index ≥ 15 with ≥ 50% central apneic events. The relation of natriuretic peptide concentrations to CSA was evaluated by estimation of ORs and receiver operator characteristics (ROCs). Results:Twenty-seven subjects (61%) had CSA, with men more frequently affected than women (73% vs 27%; OR, 7.1; P =.01); given that only three women had CSA, further analysis was restricted to men. Subjects with CSA had higher mean ANP (4,336 pg/mL vs 2,510 pg/mL, P =.03) and BNP concentrations (746 pg/mL vs 379 pg/mL, P =.05). ANP and BNP concentrations were significantly related to CSA (OR, 3.7 per 3,000 pg/mL, P =.03 and OR, 1.5 per 200 pg/mL, P =.04, respectively), whereas age, LVEF, and New York Heart Association functional class were not. Concentrations of ANP and BNP were predictive of CSA as ROC demonstrated areas under the curve of 0.75 and 0.73, respectively. Conclusions:Risk of CSA is related to severity of HF. ANP and BNP concentrations performed similarly for detection of CSA; low concentrations appear associated with low risk for CSA in men.
AB - Background: Central sleep apnea (CSA) is frequent among patients with heart failure (HF) and associated with increased morbidity and mortality. Elevated cardiac filling pressures promote CSA and atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) secretion. We hypothesized that circulating natriuretic peptide concentrations predict CSA. Methods:Consecutive patients with HF (n = 44) with left ventricular ejection fraction (LVEF) ≤35% underwent polysomnography for detection of CSA. CSA was defined as an apnea-hypo pnea index ≥ 15 with ≥ 50% central apneic events. The relation of natriuretic peptide concentrations to CSA was evaluated by estimation of ORs and receiver operator characteristics (ROCs). Results:Twenty-seven subjects (61%) had CSA, with men more frequently affected than women (73% vs 27%; OR, 7.1; P =.01); given that only three women had CSA, further analysis was restricted to men. Subjects with CSA had higher mean ANP (4,336 pg/mL vs 2,510 pg/mL, P =.03) and BNP concentrations (746 pg/mL vs 379 pg/mL, P =.05). ANP and BNP concentrations were significantly related to CSA (OR, 3.7 per 3,000 pg/mL, P =.03 and OR, 1.5 per 200 pg/mL, P =.04, respectively), whereas age, LVEF, and New York Heart Association functional class were not. Concentrations of ANP and BNP were predictive of CSA as ROC demonstrated areas under the curve of 0.75 and 0.73, respectively. Conclusions:Risk of CSA is related to severity of HF. ANP and BNP concentrations performed similarly for detection of CSA; low concentrations appear associated with low risk for CSA in men.
UR - http://www.scopus.com/inward/record.url?scp=83455201043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83455201043&partnerID=8YFLogxK
U2 - 10.1378/chest.10-2472
DO - 10.1378/chest.10-2472
M3 - Article
C2 - 21636668
AN - SCOPUS:83455201043
SN - 0012-3692
VL - 140
SP - 1517
EP - 1523
JO - Diseases of the chest
JF - Diseases of the chest
IS - 6
ER -